Royal Bank Of Canada Nutri Band Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.35 - $6.16 $117,367 - $215,815	-35,035 Reduced 99.93%	25 $0
Q1 2024 Nov 05, 2024	BUY	$2.3 - $4.52 $80,580 - $158,358	35,035 Added 140140.0%	35,060 $158,000
Q1 2024 May 15, 2024	BUY	$2.3 - $4.52 $80,440 - $158,082	34,974 Added 40667.44%	35,060 $158,000
Q4 2023 Feb 14, 2024	SELL	$1.93 - $3.02 $67 - $105	-35 Reduced 28.93%	86 $0
Q3 2023 Nov 14, 2023	SELL	$2.38 - $4.63 $14 - $27	-6 Reduced 4.72%	121 $0
Q2 2023 Aug 14, 2023	BUY	$2.04 - $3.86 $259 - $490	127 New	127 $0
Q3 2022 Nov 14, 2022	BUY	$3.49 - $7.83 $293 - $657	84 New	84 $0

284K

Ticker NTRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,803,260
Market Cap $30.7M
Description
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid the...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.